Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) ROCE %: 23.84% (As of Mar. 2026)


IST:ONCSM Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
81 GF Score
Price ₺252.00
GF Value ₺252.15
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROCE %?

Oncosem Onkolojik Sistemlernayi ve Ticaret AS IST:ONCSM +0.40% 81 ROCE % is 23.84% as of Mar. 2026. GuruFocus rates IST:ONCSM with a GF Score™ of 81/100 and a GF Value™ of ₺252.15 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's annualized ROCE % for the quarter that ended in Mar. 2026 was 23.84%.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS  (IST:ONCSM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROCE % Related Terms

Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROCE % Historical Data

* Premium members only.

The historical data trend for Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROCE % Chart

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 91.48 -0.16 -39.73 -5.24 24.76

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.70 -9.32 24.71 62.90 23.84
IST:ONCSM
81GF Score
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROCE % Calculation

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=107.09/( ( (501.244 - 105.698) + (624.16 - 154.829) )/ 2 )
=107.09/( (395.546+469.331)/ 2 )
=107.09/432.4385
=24.76 %

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=122.656/( ( (624.16 - 154.829) + (792.572 - 232.977) )/ 2 )
=122.656/( ( 469.331 + 559.595 )/ 2 )
=122.656/514.463
=23.84 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 23.84% mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a ROCE % of 23.84% as of Mar. 2026.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROCE % too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROCE % is 23.84%. The Medical Devices & Instruments industry median ROCE % is 2.23. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 23.84% is 969.1% above this industry median. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROCE % compare to ABT and SYK?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROCE % of 23.84% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 23.84% is 969.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROCE % of 23.84% is 969.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROCE % is 23.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺252.15, compared to a current price of ₺252.00 — trading 0.1% below its estimated fair value. The current ROCE % is 23.84% and 969.1% above the Medical Devices & Instruments industry median of 2.23. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current ROCE % is 23.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued. The current stock price of ₺252.00 is trading 0.1% below its estimated GF Value™ of ₺252.15. GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.

Key valuation signals for IST:ONCSM:

  • ROCE %: 23.84%
  • GF Value™: ₺252.15 vs. price of ₺252.00 (0.1% below fair value)
  • GF Score™: 81/100 with 4 warning signs
  • Industry Position: 969.1% above the Medical Devices & Instruments median

No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description

Address Mutlukent Mah. 1988 Cad. No: 12, Cankaya, Ankara, TUR
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is specialized in the production of equipment and medical devices used in cancer treatment.
81GF Score

Get the complete analysis for IST:ONCSM

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺252.00
Price
₺252.15
GF Value